65660 Federal Register / Vol. 60, No. 244 / Wednesday, December 20, 1995 / Notices

Title Number of

respondents

Frequency

of response

Number of

responses

Hours per

response

Total burden hours

Biennial Entity Verification Document ...................................................... 5,750 1 5,750 .25 1,438

Entity File Update ..................................................................................... 1,150 1 1,150 .25 288

Estimated Total Annual Burden:

167,489 hours

Written comments and

recommendations concerning the

proposed information collection should

be sent within 30 days of this notice to:

Allison Eydt, Human Resources and

Housing Branch, Office of Management

and Budget, New Executive Office

Building, Room 10235, Washington,

D.C. 20503.

Dated: Decmber 14, 1995.

J. Henry Montes,

Associate Administrator for Policy

Coordination

[FR Doc. 95–30885 Filed 12–19–95; 8:45 am]

BILLING CODE 4160–15–U

National Institutes of Health

Opportunity For Licensing: Sequence

Modification of Oligonucleotide

Primers to Manipulate Non-Templated

Nucleotide Addition

AGENCY: National Institutes of Health,

Pubic Health Service, DHHS.

ACTION: Notice.

SUMMARY: The National Institutes of

Health (NIH) seeks licensees to

commercialize a method to manipulate

non-templated nucleotide addition to

ensure that all amplified DNA products

of polymerase chain reaction (PCR) are

either specifically modified or

unmodified.

This technology was developed by Dr.

Jeffrey R. Smith and Dr. John Carpten of

the National Center for Human Genome

Research and Dr. Michael Brownstein of

the National Institute of Mental Health.

The invention embodied in U.S.

Provisional Patent Application 60/005,

761 filed October 20, 1995, entitled

‘‘Sequence Modification of

Oligonucleotide Primers to Manipulate

Non-Templated Nucleotide Addition,’’

is owned by an agency of the

U.S.Government and is available for

licensing in the U.S. in accordance with

35 U.S.C. 207 or pursuant to 42 U.S.C.

241 to achieve expeditious

commercialization of results of

federally-funded research and

development.

ADDRESSES: Requests for a summary of

the technology or other questions and

comments concerning the biomedical

aspects of this technology should be

directed to: Dr. Ronald King, National

Center for Human Genome Research,

9000 Rockville Pike, Building 31, Room

3B13, Bethesda, MD 20892; Telephone:

301/402–2537; Fax 301/402–9722.

Requests for a copy of the patent

application, license application form, or

other questions and comments

concerning the licensing of this

technology should be directed to: Carol

Lavrich, Office of Technology Transfer,

National Institutes of Health, 6011

Executive Boulevard, Suite 325,

Rockville, MD 20852–3804; Telephone

301/496–7735 ext 287; Fax 301/402–

0220. A signed Confidential Disclosure

Agreement will be required to receive a

copy of the patent application.

SUPPLEMENTARY INFORMATION:

Thermostable DNA polymerases are

employed in PCR to amplify DNA for

sizing in medical diagnostics, forensics,

and genotyping, as well as for molecular

cloning. Several of these enzymes,

including the widely used Taq DNA

polymerase, can catalyze non-templated

addition of a nucleotide (predominantly

adenosine) to the 3′ end of amplification

products. As a result, an amplified DNA

fragment may be incorrectly sized by

one base pair in length and introduce

error into a genotyping study.

Artifactual variations in marker size

may adversely impact interpretations of

family relationships, medical diagnosis,

and forensics. Moreover, full

automation of genotyping has been

hampered by the necessity of manually

editing collected data to correct for

allele misidentification due to the

unpredictability of non-templated

nucleotide addition. In addition, TA

cloning methods that rely upon the

modification will often fail when the

amplified DNA is not modified.

In response to this problem, Drs.

Smith, Carpten, and Brownstein have

characterized short DNA sequences

(‘‘tails’’) that may be added to the

unlabeled primer of a PCR primer pair

to confer modification by a thermostable

DNA polymerase, or to protect from the

modification. This allows uniformity in

allele sizing that is essential for

automated genotyping. Furthermore,

this prevents introduction of error and

enables high TA cloning efficiency.

The NIH seeks licensee(s), who in

accordance with requirements and

regulations governing the licensing of

government-owned inventions (37 CFR

part 404), have the most meritorious

plan for the development of this method

to meet the needs of the public and with

the best terms for the NIH. The criteria

that NIH will use to evaluate exclusive

or non-exclusive license applications

will include those set forth by 37 CFR

404.7(a)(1)(ii)–(iv).

Dated: December 8, 1995.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 95–30935 Filed 12–19–95; 8:45 am]

BILLING CODE 4140–01–M

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

HHS.

ACTION: Notice.

SUMMARY: The invention listed below is

owned by an agency of the U.S.

Government and is available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of federally

funded research and development.

Foreign patent applications are filed on

selected inventions to extend market

coverage for U.S. companies and may

also be available for licensing.

ADDRESSES: Licensing information and a

copy of the U.S. patent application

referenced below may be obtained by

contacting Robert Benson at the Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804 (telephone 301/

496–7056 ext 267; fax 301/402–0220). A

signed Confidential Disclosure

Agreement will be required to receive a

copy of the patent application.

Immunogenic Chimeras Comprising

Nucleic Acid Sequences Encoding

Endoplasmic Reticulum Signal

Sequence Peptides and at Least One

Other Peptide, and Their Uses in

Vaccines and Disease Treatments

Nicholas P. Restifo, Steven A. Rosenberg,

Jack R. Bennink, Igor Bacik, and Jonathan

W. Yewdell (NCI)

Serial Number 08/032,902 filed March 17,

1993

This invention concerns the use of

chimeric peptides as vaccines for the

cellular immune system. One portion of

the chimeric peptide, the ER signal

peptide, serves to transport the chimeric